Open-label Extension Study of ADP101

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

March 14, 2022

Primary Completion Date

February 27, 2024

Study Completion Date

February 27, 2024

Conditions
Food Allergy
Interventions
BIOLOGICAL

ADP101

Active dry powder formulation at various volumes.

Trial Locations (14)

27599

Study Site, Chapel Hill

29420

Study Site, Charleston

30060

Study Site, Marietta

30329

Study Site, Atlanta

33620

Study Site, Tampa

45229

Study Site, Cincinnati

48108

Study Site, Ann Arbor

61761

Study Site, Normal

80230

Study Site, Denver

80907

Study Site, Colorado Springs

90274

Study Site, Rolling Hills Estates

92123

Study Site, San Diego

92691

Study Site, Mission Viejo

98115

Study Site, Seattle

All Listed Sponsors
lead

Alladapt Immunotherapeutics, Inc.

INDUSTRY

NCT05243719 - Open-label Extension Study of ADP101 | Biotech Hunter | Biotech Hunter